The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer

Author:

Castro Elena12,Mikropoulos Christos12,Bancroft Elizabeth K.12,Dadaev Tokhir1,Goh Chee12,Taylor Natalie12,Saunders Edward1,Borley Nigel2,Keating Diana1,Page Elizabeth C.1,Saya Sibel1,Hazell Stephen3,Livni Naomi3,deSouza Nandita4,Neal David56,Hamdy Freddie C.7,Kumar Pardeep2,Antoniou Antonis C.8,Kote-Jarai Zsofia1,Eeles Rosalind A.12,

Affiliation:

1. Oncogenetics Team, The Institute of Cancer Research, London, United Kingdom

2. Academic Urology Unit, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom

3. Histopathology Department, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom

4. Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton, United Kingdom

5. Department of Oncology, Cancer Research UK Cambridge Institute, Cambridge, United Kingdom

6. Department of Surgery, Cancer Research UK Cambridge Institute, Cambridge, United Kingdom

7. Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom

8. Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom

Abstract

Abstract Background. A better assessment of individualized prostate cancer (PrCa) risk is needed to improve screening. The use of the prostate-specific antigen (PSA) level for screening in the general population has limitations and is not currently advocated. Approximately 100 common single nucleotide polymorphisms (SNPs) have been identified that are associated with the risk of developing PrCa. The PROFILE pilot study explored the feasibility of using SNP profiling in men with a family history (FH) of PrCa to investigate the probability of detecting PrCa at prostate biopsy (PB). The primary aim of this pilot study was to determine the safety and feasibility of PrCa screening using transrectal ultrasound-guided PB with or without diffusion-weighted magnetic resonance imaging (DW-MRI) in men with a FH. A secondary aim was to evaluate the potential use of SNP profiling as a screening tool in this population. Patients and Methods. A total of 100 men aged 40–69 years with a FH of PrCa underwent PB, regardless of their baseline PSA level. Polygenic risk scores (PRSs) were calculated for each participant using 71 common PrCa susceptibility alleles. We treated the disease outcome at PB as the outcome variable and evaluated its associations with the PRS, PSA level, and DW-MRI findings using univariate logistic regression. Results. Of the 100 men, 25 were diagnosed with PrCa, of whom 12 (48%) had clinically significant disease. Four adverse events occurred and no deaths. The PSA level and age at study entry were associated with PrCa at PB (p = .00037 and p = .00004, respectively). Conclusion. The results of the present pilot study have demonstrated that PB is a feasible and safe method of PrCa screening in men with a FH, with a high proportion of PrCa identified requiring radical treatment. It is feasible to collect data on PrCa-risk SNPs to evaluate their combined effect as a potential screening tool. A larger prospective study powered to detect statistical associations is in progress.

Funder

Ronald and Rita McAulay Foundation

Cancer Research UK

European Society for Medical Oncology Clinical Research Fellowship

American Society of Clinical Oncology

Cancer Foundation

Genetic Associations and Mechanisms in Oncology

NIH ELLIPSE

Cancer Research U.K. Senior Cancer Research Fellow

Institute of Cancer Research

Royal Marsden National Health Service

NIH

Biomedical Research Centre

Royal Marsden NHS Foundation Trust

iCOGS infrastructure came from the European Community’s Seventh Framework Programme

Cancer Research U.K.

Post-Cancer Genome-Wide Association Study Initiative

Department of Defense

Canadian Institutes of Health Research

CIHR Team in Familial Risks of Breast Cancer

Komen Foundation for the Cure

Breast Cancer Research Foundation

Ovarian Cancer Research Fund

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3